龙慈仙胶囊联合CapeOx方案治疗大肠癌临床观察

Clinical observation on Longcixian capsule combined with CapeOx regimen in the treatment of colorectal cancer

目的观察龙慈仙胶囊联合CapeOx方案治疗大肠癌的临床疗效及对细胞免疫功能的影响。方法随机选择2019年10月—2020年10月于陕西省中医医院肿瘤科住院确诊为中晚期大肠癌患者60例,随机分为2组,对照组30例给予CapeOx方案化疗,观察组30例在对照组化疗基础上加服龙慈仙胶囊,连续治疗2个周期(6周)。观察2组治疗后细胞免疫功能(CD3^(+)CD4^(+)、CD3^(+)CD8^(+)、CD4^(+)/CD8^(+))、生活质量KPS评分、骨髓抑制程度及临床疗效。结果治疗2个周期后,观察组CD3^(+)CD4^(+)、CD4^(+)/CD8^(+)及2组生活质量KPS评分均较治疗前明显升高(P均<0.05),且观察组均明显高于对照组(P<0.05);治疗2个周期后,观察组CD3^(+)CD8^(+)明显低于治疗前及对照组(P均<0.05),对照组无明显变化(P>0.05)。观察组骨髓抑制发生率为40.0%(12/30),对照组为66.7%(20/30),观察组显著低于对照组(P<0.05)。观察组临床总有效率为73.3%(22/30),对照组为50.0%(15/30),观察组显著高于对照组(P<0.05)。结论CapeOx方案化疗联合龙慈仙胶囊治疗可明显改善大肠癌患者免疫功能、生活质量,减轻骨髓抑制程度,提高临床疗效。

Objective It is to observe the clinical efficacy of Longcixian capsule combined with CapeOx regimen in the treatment of colorectal cancer and its effect on cellular immune function.Methods Sixty patients with advanced colorectal cancer who were hospitalized in the Department of Oncology,Shaanxi Provincial Hospital of Traditional Chinese Medicine from October 2019 to October 2020 were randomly selected and randomly divided into 2 groups.30 cases in the control group were treated with CapeOx chemotherapy,and 30 cases in the observation group were treated with Longcixian capsules for 2 consecutive cycles(6 weeks)on the basis of chemotherapy in the control group.The cellular immune function(CD3^(+)CD4^(+),CD3^(+)CD8^(+),CD4^(+)/CD8^(+)),KPS score of quality of life,degree of bone marrow suppression and clinical efficacy were observed in the two groups after treatment.Results After 2 cycles of treatment,CD3^(+)CD4^(+),CD4^(+)/CD8^(+)in the observation group,and KPS scores of quality of life in both groups were significantly higher than those before treatment(P<0.05),and the observation group was significantly higher than the control group(P<0.05).After 2 cycles of treatment,CD3^(+)CD8^(+)in the observation groups was significantly lower than that before treatment and in the control group(P<0.05),and no obvious changes was found in the control group(P>0.05).The incidence of bone marrow suppression was 40.0%(12/30)in the observation group and 66.7%(20/30)in the control group,and the observation group was significantly lower than the control group(P<0.05).The total clinical effective rate was 73.3%(22/30)in the observation group and 50.0%(15/30)in the control group,and the observation group was significantly higher than the control group(P<0.05).Conclusion CapeOx regimen chemotherapy combined with Longcixian capsules can significantly improve immune function and quality of life,reduce the degree of bone marrow suppression,and improve clinical efficacy in the treatment of patients with colorectal cancer.